XML 22 R9.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Reporting | 9 Months Ended
--- | ---
Aug. 31, 2022
Segment Reporting [Abstract] |
Segment Reporting | Note 2 – Segment Reporting The Company is organized in three reportable segments: 1. The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”). 2. The manufacture of PrepaCyte® CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the PrepaCyte® CB units (the “PrepaCyte®-CB”). 3. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenue is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States, and around the world. The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2022 and 2021:
|  | For the three months ended August 31, |
|  | 2022 |  |  | 2021 |
Net revenue: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 7,522,134 |  |  | $ | 7,326,516 |
PrepaCyte CB |  |  | 21,000 |  |  |  | 18,200 |
Public cord blood banking |  |  | 137,825 |  |  |  | 158,936 |
Total net revenue |  | $ | 7,680,959 |  |  | $ | 7,503,652 |
Cost of sales: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 1,883,400 |  |  | $ | 1,943,419 |
PrepaCyte CB |  |  | 10,622 |  |  |  | 53,498 |
Public cord blood banking |  |  | 454,733 |  |  |  | 462,021 |
Total cost of sales |  | $ | 2,348,755 |  |  | $ | 2,458,938 |
Operating profit: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 1,268,146 |  |  | $ | 1,941,976 |
PrepaCyte CB |  |  | 3,433 |  |  |  | (42,193 | )
Public cord blood banking |  |  | (317,268 | ) |  |  | (303,445 | )
Total operating profit |  | $ | 954,311 |  |  | $ | 1,596,338 |
Depreciation and amortization: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 274,598 |  |  | $ | 262,229 |
PrepaCyte CB |  |  | 6,945 |  |  |  | 6,894 |
Public cord blood banking |  |  | 360 |  |  |  | 359 |
Total depreciation and amortization |  | $ | 281,903 |  |  | $ | 269,482 |
Interest expense: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 365,349 |  |  | $ | 335,870 |
PrepaCyte CB |  |  | — |  |  |  | — |
Public cord blood banking |  |  | — |  |  |  | — |
Total interest expense |  | $ | 365,349 |  |  | $ | 335,870 |
|  | For the nine months ended August 31, |
|  | 2022 |  |  | 2021 |
Net revenue: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 22,159,702 |  |  | $ | 21,224,033 |
PrepaCyte CB |  |  | 75,600 |  |  |  | 56,200 |
Public cord blood banking |  |  | 337,405 |  |  |  | 289,231 |
Total net revenue |  | $ | 22,572,707 |  |  | $ | 21,569,464 |
Cost of sales: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 5,343,455 |  |  | $ | 5,453,203 |
PrepaCyte CB |  |  | 63,934 |  |  |  | 129,581 |
Public cord blood banking |  |  | 1,246,108 |  |  |  | 1,111,022 |
Total cost of sales |  | $ | 6,653,497 |  |  | $ | 6,693,806 |
Operating profit: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 4,538,058 |  |  | $ | 5,743,184 |
PrepaCyte CB |  |  | (9,168 | ) |  |  | (94,065 | )
Public cord blood banking |  |  | (909,783 | ) |  |  | (822,452 | )
Total operating profit |  | $ | 3,619,107 |  |  | $ | 4,826,667 |
Depreciation and amortization: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 818,081 |  |  | $ | 536,823 |
PrepaCyte CB |  |  | 20,834 |  |  |  | 20,683 |
Public cord blood banking |  |  | 1,080 |  |  |  | 661 |
Total depreciation and amortization |  | $ | 839,995 |  |  | $ | 558,167 |
Interest expense: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 947,968 |  |  | $ | 957,479 |
PrepaCyte CB |  |  | — |  |  |  | — |
Public cord blood banking |  |  | — |  |  |  | — |
Total interest expense |  | $ | 947,968 |  |  | $ | 957,479 |
The following table shows the assets by segment as of August 31, 2022 and November 30, 2021:
|  | As of |  |  | As of |
|  | August 31, 2022 |  |  | November 30, 2021 |
Assets: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 56,548,260 |  |  | $ | 50,170,887 |
PrepaCyte CB |  |  | 238,636 |  |  |  | 250,591 |
Public cord blood banking |  |  | 9,978,397 |  |  |  | 10,240,598 |
Total assets |  | $ | 66,765,293 |  |  | $ | 60,662,076 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration